Condition Directory

Obesity clinical trials

Directory of U.S. ClinicalTrials.gov public records for Obesity. Browse Obesity recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

970

Shown on this page

Local recruiting

170

Local phase groups

The trial list below is retrieved from the live ClinicalTrials.gov search API for Obesity. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 970 matching trials for Obesity.

Indexed local directory records.

Phase distribution

Not applicable 472

Phase 3 112

Phase 2 109

Phase 1 87

Phase 4 44

Early Phase 1 13

Top locations

Dallas, Texas 97 Boston, Massachusetts 77 Houston, Texas 76 Chicago, Illinois 74 New York, New York 72 San Antonio, Texas 65

Top sponsors

Novo Nordisk A/S 76 Eli Lilly and Company 45 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 35 University of Colorado, Denver 27 Mayo Clinic 23 Vanderbilt University Medical Center 15

Top therapies

Semaglutide 32 Tirzepatide 27 Liraglutide 15 Orforglipron 11 NNC0487-0111 10 Cagrilintide 9

Indexed official records

Open in full search

Conditions: Obesity, Obesity Prevention, Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Weight Management
Interventions: Comprehensive Multidisciplinary Obesity Care, Implementation as Usual Control; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 5 Years and older
Enrollment: 6,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Low Back Pain (CLBP), Obesity, Overweight
Interventions: Placebo, Retatrutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more

Conditions: Diabetes Mellitus, Obesity, Overweight
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Lomita, California + 12 more

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anniston, Alabama • Walnut Creek, California • Orlando, Florida + 9 more

Conditions: Obesity
Interventions: ABBV-295, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Obesity
Interventions: Community Asset Mapping (CAM), Community-Engaged Health Coaching and Navigation, Health Literacy and Culturally Tailored Materials, Obesity Toolkit for Primary Care Providers, Primary Care Provider Training, Self-Monitoring and Remote Patient Monitoring of weight and physical activity; Other · Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Avondale, Louisiana • Bastrop, Louisiana • Baton Rouge, Louisiana + 15 more

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Ventura, California • New Haven, Connecticut • Stamford, Connecticut + 12 more

Conditions: Obesity, Weight Gain
Interventions: Placebo, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 15
States / cities: Los Angeles, California • Sacramento, California • Wilmington, Delaware + 12 more

Conditions: Diabetes, Type 2, Obesity, Overweight, Overweight and/or Obesity, Type 2 Diabetes
Interventions: PF-08653944, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 35
States / cities: Anaheim, California • Canoga Park, California • Cerritos, California + 30 more

Conditions: Obesity
Interventions: Child Nutrition Counseling, Introduction of Milk Type; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 23 Months to 48 Months
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: Cardiometabolic Syndrome, Obesity
Interventions: Intermittent Short Sleep (ISS), Social Jetlag (SJL), Sustained Adequate Sleep (SAS); Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Osteoarthritis, Knee, Overweight
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Escondido, California • Lancaster, California • Palm Springs, California + 14 more

About this Obesity clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Obesity as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Obesity.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Obesity clinical trials

Filter and sort this condition

Phase distribution

Top locations

Top sponsors

Top therapies

Indexed official records

Advancing Biopsychosocial Care Training Initiative

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health

Impact of Yo-Yo Sleep on Cardiometabolic Health

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

About this Obesity clinical trials directory page